TNFerade is a radioinducible adenoviral vector expressing tumor necrosis factor-a (TNF-a) (Ad.Egr-TNF) currently in a phase III trial for inoperable pancreatic cancer. We studied B16-F1 melanoma tumors in TNF receptor wild-type (C57BL/6) and deficient (TNFR1,2À/À and TNFR1À/À) mice. Ad.Egr-TNF þ IR inhibited tumor growth compared with IR in C57BL/6 but not in receptordeficient mice. Tumors resistant to TNF-a were also sensitive to Ad.Egr-TNF þ IR in C57BL/6 mice. Ad.Egr-TNF þ IR produced an increase in tumor-associated endothelial cell apoptosis not observed in receptor-deficient animals. Also, B16-F1 tumors in mice with germline deletions of TNFR1,2, TNFR1 or TNF-a, or in mice receiving anti-TNF-a exhibited radiosensitivity. These results show that tumor-associated endothelium is the principal target for Ad.Egr-TNF radiosensitization and implicate TNF-a signaling in tumor radiosensitivity.
Introduction
Tumor radioresistance resulting in recurrence is an important problem in cancer therapy. Despite intensive study, debate exists as to whether the appropriate targets for radiosenstization are tumor cells or tumor stroma, especially the tumor endothelium. [1] [2] [3] [4] [5] [6] Although angiogenesis inhibitors have had an impact on clinical oncology practice and are approved for use alone or with chemotherapy, no antiangiogenic compound has shown sufficient activity as a radiosensitizer to be approved for routine use. [7] [8] [9] An antiangiogenic gene therapy strategy currently under clinical investigation uses a replicationdefective adenovirus encoding the radio-inducible/chemoinducible DNA sequences of the egr-1 promoter ligated upstream of the cDNA for human tumor necrosis factor-a (TNF-a) (TNFerade, GenVec, Gaithersburg, MD). 10 Phase I and II clinical trials using TNFerade and radiotherapy have shwn complete pathological responses in esophageal, 11 rectal 12 and pancreatic cancer and in patients with melanoma 13 and sarcoma. 14 Results of a Phase III trial in locally advanced unresectable pancreatic cancer are encouraging in that TNFerade combined with chemotherapy/radiotherapy has shown a survival advantage compared with chemotherapy/ radiotherapy alone. 15 Tumor necrosis factor-a is a cytokine secreted by a variety of normal and tumor cells and is physiologically important in antimicrobial and antitumor immunity. [16] [17] [18] TNF-a is a major effector of inflammation and has been implicated in tumor angiogenesis. 19, 20 The actions of TNF-a are mediated by two receptors, TNF receptor 1 (TNFR1, p55kd) and TNF receptor 2 (R2, p75kd). Most cytotoxic/antitumor activities of TNF-a are mediated by TNFR1, 21 whereas TNFR2 signals primarily in cells of the immune system. In some cells interactions between TNFR1 and TNFR2 receptors have been reported. 22, 23 In experimental murine tumors, necrosis occurs after systemic TNF-a administration mediated by the antivascular effects of TNF-a, likely through induction of a procoagulation environment 24, 25 and tumor vessel thrombosis. 26 These results stimulated human clinical trials employing systemic TNF-a, which were abandoned owing to toxicity. 27 More recently, combinations of TNF-a with small-molecule inhibitors of XIAP (X-linked inhibitor of apoptosis proteins) 28, 29 and studies of the interaction of TNF-a signaling with growth factors have inspired studies of tumor cell killing with TNF-a, suggesting that tumor cells might be an underinvestigated TNF-a target. 30 Despite these studies, the clinical use of TNF-a in cancer therapy is currently restricted to local tumor arterial perfusion, whereby arteries of the extremities of patients with locally advanced recurrent melanoma and soft tissue sarcoma are perfused with TNF-a and gross tumor necrosis is induced. 31, 32 Earlier we reported that treatment with TNFerade significantly reduces lymphatic metastases by an unknown host dependent response. 33 In this study, using TNF receptor 1, 2 and TNF receptor 1 knockout mouse models and tumor cells deficient in TNF receptor 1, we show that increasing apoptosis of tumorassociated endothelium represents a mechanism for tumor radiosensitization. Our findings also suggest translational strategies in radiotherapy, which involve modulating TNF-a signaling.
Materials and methods
Cell culture B16F-1 murine melanoma cells were obtained from the American Type Culture Collection (Manassas, VA) and were cultured using RPMI 1640 culture medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Invitrogen). BFS-2C (TNFR1À/À) cells (kindly provided by Daniela Mannel, University of Regensburg, Regensburg, Germany) 21 were cultured using RPMI 1640 culture medium supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The cell cultures were maintained at 37 1C in a humidified environment containing 5% CO 2 .
Mice C57BL/6-NCr mice were obtained from FCRI-Taconic (Germantown, NY).
B6;129S-Tnfrsf1a tm1Imx Tnfrsf1b tm1Imx /J (TNFR1, 2À/À), C57BL/6-Tnfrsfa tm1Imx /J (TNFR1À/À) and B6:129S-Tnftm1Gkl/J (TNFÀ/À) mouse breeding pairs were obtained from Jackson Laboratories (Bar Harbor, ME). Animals were 5-7 weeks of age when experimentation began. The care and treatment of experimental animals was in accordance with institutional guidelines.
Tumor experiments B16F-1 and BFS-2C cells (2 Â 10 6 cells in 100 ml phosphate-buffered saline) were injected subcutaneously into the right hindlimb. Five to seven days after injections the tumor volume was 150-200 mm 3 . Tumor volume was determined by direct measurement with calipers and calculated by the formula (length Â width Â depth/2). At the initiation of treatment (day 0) animals were divided into four treatment groups with equal mean tumor volumes: control (10 ml adenoviral buffer, 3% sucrose phosphate-buffered saline), Ad.Egr-TNF (or Ad.Empty), 20 Gy, and Ad.Egr-TNF þ 20 Gy (or Ad.Empty þ 20 Gy). Animals receiving virus were injected intratumorally with 2 Â 10 9 particle units (p.u.) suspended in 10 ml adenovirus buffer (3% sucrose in phosphate-buffered saline) on days 0 and 1. Control mice and mice treated with radiation were injected intratumorally with 10 ml adenoviral buffer. Twenty Gy was delivered in a single dose using a Phillips orthovoltage X-ray generator operating at 250 kV and 15 mA on day 1. Mice were restrained in plexiglass cages and all but the tumor-bearing hindlimb were shielded with lead. At the conclusion of each experiment the animals were euthanized using CO 2 followed by cervical dislocation in accordance with institutional guidelines.
Enbrel treatment
Alzet mini-osmotic pump model 2001 (pumping rate 1.0 ml h
À1
) was ordered from Durect (Cupertino, CA). C57BL/6 mice were injected with 2 Â 10 6 B16F-1 cells. When tumors reached the appropriate volume, the mice were prepared for implantation of the Alzet pumps. Enbrel (etanercept) was diluted to 5 mg ml À1 in sterile water. Each pump was loaded per the manufacturer's instructions with 200 ml Enbrel or 200 ml phosphatebuffered saline (control). The fur between the shoulder blades of the animal was shaved and washed with betadyne swabs. Animals were anesthetized with isofluorane. A small incision was made just large enough for the pump to pass through. Using a hemostat, the skin was separated from the surrounding tissue. The pump was inserted and the wound sutured. Ad.Egr-TNF þ 20 Gy treatment was began the next day and conducted as described above. These experiments were terminated at day 7, because at that time the Enbrel in the pump was depleted.
Human TNF-a quantification B16F-1 cells were injected into C57BL/6 mice followed by treatment with Ad.Egr-TNF, 20 Gy, and Ad.Egr-TNF þ 20 Gy. Twenty-four hours later, tumors were excised and homogenized for 30 s in cold lysis buffer (150 mM NaCl; 10 mM Tris pH ¼ 7.5; 5 mM EDTA pH ¼ 7.5; EDTA-free protease inhibitor cocktail, Pierce Biotechnology, Rockford, IL). Subsequently, samples were freeze-thawed (30 s in liquid nitrogen; 2.5 min in 37 1C water bath; four cycles) and spun at 2000 r.p.m. for 5 min. Supernatants were collected and stored at À80 1C. All samples (24 h samples; n ¼ 16; equally distributed among control, 20 Gy, Ad.Egr-TNF, and Ad.Egr-TNF þ 20 Gy) were normalized to 3 mg ml À1 total protein, pooled by treatment group, diluted 10-fold, and assayed for human TNF-a in triplicate using ELISA (R&D Systems, Minneapolis, MN). The plates were read using a SPECTRAmax 340 plate reader running SOFTmax PRO software (Molecular Devices, Sunnyvale, CA). RNA extraction, cDNA synthesis and real-time PCR analysis cDNA was synthesized from 3.2 mg Trizol-extracted (Invitrogen) total RNA using the Superscript III cDNA Synthesis System (Invitrogen). PCR primers specific for TNFR1 (acccccaggactcaggtact and tccagccttctcctctttga) and HPRT1 (tcagtcaacgggggacataaa and ggggctgtactgct taaccag) were used to determine the relative expression of the targeted gene. The PCR reaction was performed using an ABI 7900 HT (Applied Biosystems, Forest City, CA) in a 384-well plate, in 15 ml reaction volume using 7.5 ml 2X SYBR Green PCR Mastermix (Applied Biosystems), 0.5 ml of 10 mM primer mixture and 5 ml of a 1:100 dilution of the cDNA synthesis reaction. Forty PCR cycles at 95 1C, 15 s and 60 1C, were performed after initial incubations of 50 1C for 2 min and 95 1C for 10 min. Relative expression was normalized to HPRT1 expression and calculated using the comparative C t method.
Immunohistochemistry
Three to five tumors per treatment were excised at various time points post-treatment, fixed in 10% formalin for 48 h, then embedded in paraffin. Sections of 4 mm were deparaffinized and subjected to staining using antibodies against VEGF receptor 2 (Cell Signaling Technology, 2479, Beverly, MA), CD34 (abCam, ab8158) and cleaved caspase 3 (Cell Signaling, 8120). In brief, sections were incubated with VEGFR2 (1:400) or CD34 (1:50) antibody for 1 h. After incubating with biotinylated secondary antibody (Vector Labs, Burlingame, CA), ABC-alkaline phosphatase (ABC-Ap, Vector Labs) system, together with Vector-Blue chromogen, was used to develop blue color. For double staining, slides were washed, and incubated with cleaved caspase 3 antibody (1:400) overnight at 4 1C. ABC-AP and Vulcan fast red (Biocare Medical, Concord, CA) were used to develop red color. Sections were counterstained in methyl green, and mounted with VectaMount (Vector Labs). Slides were viewed using Zeiss Axioskop microscope and images were captured using a Zeiss Axiocam digital color camera, acquired by OpenLab software. Approximately 20 viable fields ( Â 400) were randomly selected and endothelial cells in each field were counted. For apoptosis study, endothelial cells double stained by cleaved caspase 3 were counted. The percentage of apoptosis was expressed as ratio of double-stained cells over total endothelial cell numbers. Statistical analysis was conducted using mixed effect model.
Statistical analysis
Statistical significance (Pp0.05) was determined using one-way analysis of variance or student's t-test.
Results
Effects of Ad.Egr-TNF þ IR treatment on murine tumor regrowth We used a syngeneic tumor model B16-F1 melanoma to investigate the relative contributions of tumor cells and host-derived stroma to the potential radiosensitizing effects of Ad.Egr-TNF. We selected 20 Gy as an experimental dose because this approximates the largest single dose currently used in radiotherapy. To study whether treatment with Ad.Egr-TNF enhances the antitumor effects of 20 Gy, we injected C57BL/6 wild-type mice with B16-F1 tumor cells and allowed tumors to grow to a mean tumor volume of 197 ± 9 mm 3 (n ¼ 31). Data are presented as tumor regrowth in Figure 1a . We chose day Translational strategies exploiting TNF-a HJ Mauceri et al 11 after the initiation of treatment for evaluation of tumor regrowth because of the rapid growth rate of untreated B16-F1 tumors. By day 8, the mean volume of control tumors was 3012±962 mm 3 , whereas that of tumors treated with Ad.Egr-TNF alone was 2035 ± 472 mm 3 . Mice in both of these treatment groups were euthanized because of tumor burden. Figure 1b) .
Induction of human TNF-a in murine tumors
Intratumoral human TNF-a concentrations were quantified after treatment with 20 Gy, Ad.Egr-TNF or Ad.Egr-TNF þ 20 Gy. C57BL/6 mice were injected with B16-F1 tumors and treated as described for the regrowth studies. Tumors were harvested, tumor lysates prepared and TNF-a levels were determined by ELISA. No human TNF-a was detected in control and IR-treated tumor extracts. A significant increase in human TNF-a (576.4 ± 10.4 pg per mg protein) was detected in extracts from B16-F1 tumors 24 h after treatment with Ad.Egr-TNF þ 20 Gy compared with tumors treated with Ad.Egr-TNF alone (228 ± 8.24 pg per mg protein, Po0.0001, t-test, Figure 2 ). These results confirm the radiation induction of Egr-TNF in the B16-F1 tumor model.
Effects of TNF-a neutralization
To evaluate the effect of TNF-a neutralization on the antitumor effects of Ad.Egr-TNF þ IR, we conducted studies using Enbrel (etanercept), which is a dimer of two molecules of the extracellular ligand-binding portion of the TNFR2 (p75) linked to the Fc portion of human 
Effects of Ad.Egr-TNF þ IR in TNF-a-deficient mice
To further address the role of TNF-a, we engrafted B16-F1 tumors in mice with germline deletions of TNF-a (TNFÀ/À). Ad.Egr-TNF þ IR treatment significantly decreased mean tumor volume (477 ± 172 mm 3 ) compared with IR alone (742 ± 313 mm 3 , day 7, P ¼ 0.05, t-test, Figure 3 ), suggesting that the TNF-a produced by the vector enhances IR antitumor effects. Interestingly, B16-F1 tumors are more radiosensitive in TNFÀ/À mice as measured by the relative reduction in tumor volume at day 7 (V/Vo ¼ 2.4±0.4) compared with C57BL/6 mice (7.3 ± 1.8, P ¼ 0.05, t-test). These data together suggest that increasing TNF-a concentration or blocking the action of endogenous TNF-a can enhance the antitumor effects of IR.
Effects of Ad.Egr-TNF þ IR in TNF receptor-deficient mice
To investigate the potential contribution of the tumor stroma to the radiation enhancing effects of Ad.Egr-TNF, B16-F1 tumors were established in C57BL/6 mice with germline deletions of TNF receptor 1 and 2 (TNFR1,2À/À). Mice were distributed into treatment groups and treated as described above (n ¼ 46). In contrast to wild-type Figure 4a ). These results suggest that TNF-a likely mediates its antitumor effects in murine tumors through TNFR1, because the human TNF-a encoded by Ad.Egr-TNF does not bind to murine TNFR2. 34 Parallel studies were thus conducted using mice with germline deletions in TNF receptor 1 (TNFR1À/À, n ¼ 17). No significant difference in tumor regrowth was observed between the Ad.Egr-TNF þ 20 Gy group (1202±411 mm 3 ) and the 20 Gy alone group (728±211 mm 3 , day 12, P ¼ 0.49, t-test, Figure 4b) . Interestingly, B16-F1 tumors growing in TNFR1,2À/À or TNFR1À/À mice were more radiosensitive (V/Vo ¼ 1.9±0.3, day 7; V/Vo ¼ 1.7±0.2, day 6, respectively) than B16-F1 tumors grown in C57BL/6 wild-type mice (7.3 ± 1.8). These results show that host stroma represents a target for Ad.Egr-TNF radiosensitization and that the stroma influences the response of B16-F1 tumors to IR.
Effects of Ad.Egr-TNF þ IR on TNF receptor-deficient tumor cells
To further assess effects of Ad.Egr-TNF þ IR, we used B16F1 melanoma cells, which express TNFR1 35 (IC 60 ¼ 25 ng ml
À1
) and BFS-2C cells, which are methylcholanthrene-induced fibrosarcoma cells derived from a TNFR1À/À mouse. 21 The BFS-2C cells therefore do not express TNFR1 and are resistant to TNF-a killing. BFS-2C cells were injected into wild-type C57BL/6 mice and TNFR1,2À/À mice. In wild-type mice, treatment with Ad.Egr-TNF þ 20 Gy produced significant tumor regression compared to 20 Gy alone (P ¼ 0.008, day 4, P ¼ 0.01, day 7, Figure 5a ), but not in TNFR1,2À/À mice (P ¼ 0.50, at days 4 and 7, Figure 5b ). In wild-type mice, the magnitude of response to combined treatment with Ad.Egr-TNF þ IR of TNF-resistant BFS-2C fibrosarcomas (V/Vo ¼ 2.1 ± 0.1) is comparable to that seen in TNF-sensitive B16-F1 tumors (V/Vo ¼ 2.5±0.6), which suggests that the stroma represents the principal treatment target of Ad.Egr-TNF þ IR. In wild-type mice, BFS-2C tumors exhibit increased radiosensitivity (V/Vo ¼ 3.0 ± 0.2, day 7) compared with B16-F1 tumors (V/Vo ¼ 7.3 ± 1.8, day 8). These findings considered with the results above implicate the TNF-TNFR signaling pathway in the radiation response of tumor cells and tumor stroma.
To further investigate the role of TNF-a in tumor radiosensitization, we constructed tumor cells that are relatively resistant to the cytotoxic effects of TNF-a by transfecting B16-F1 tumor cells with shRNA to TNFR1. Silencing of TNFR1 expression was confirmed by quantitative real-time PCR. Clone Tr-4 exhibited the lowest expression of TNFR1 (33% of control) and was selected for further study. Tr-4 cells exposed to 100 ng ml À1 TNF-a were more resistant to TNF-a killing than the B16-F1 parental cells (surviving fraction: Tr-4 ¼ 61.4±2.2%; B16-F1 ¼ 49.7±3.9%, P ¼ 0.011, t-test). The Tr-4 clone was then injected into wild-type C57BL/6 mice to evaluate the response in vivo. At day 7, the mean tumor volume of the animals treated with Ad.Egr-TNF þ 20 Gy was significantly decreased compared to the animals treated with 20 Gy alone (P ¼ 0.022, t-test). These results support the data described above, which shows that the response to Ad.Egr-TNF þ IR is primarily stromal. It is also noteworthy that Tr-4 and BSF-2C tumors are more radiosensitive than B16-F1 tumors in C57BL/6 hosts. These results therefore suggest that TNF-TNFR blockade in the tumor cells and/or tumor stroma enhances tumor killing by IR.
Ad.Egr-TNF þ IR targets tumor-associated endothelial cells Our findings suggest that the tumor-associated endothelium is the principal target for Ad.Egr-TNF radiosensitization. Both radiation and TNF-a have been reported to mediate endothelial cell apoptosis. To investigate endothelial cell death after treatment with Ad.Egr-TNF þ IR, we double-stained paraffin-embedded tissue sections for VEGF receptor 2 (confirmed by CD34 staining) and cleaved (activated) caspase 3 (apoptosis marker). In tumor-associated endothelial cells (TAEC) from untreated control tumors from C57BL/6 mice, 6.4 ± 0.9% of endothelial cells per high power field stained positive for cleaved caspase 3 ( Figure 6 ). In contrast, TAEC from untreated control tumors in TNFR1,2À/À mice exhibited 12.4 ± 1.2% apoptosis, consistent with greater numbers of TAEC per high power field in untreated control tumors in C57BL/6 (17±1.3) compared with untreated control tumors in TNFR1,2À/À (13 ± 0.7, P ¼ 0.05). In C57BL/6 mice, exposure to 20 Gy produced a significant increase in TAEC apoptosis (Po0.001) compared with untreated control animals ( Figure 6 ) at 18.3, 16.1 and 15.2% for 1, 4 and 24 h post-treatment, respectively. Ad.Egr-TNF treatment alone also produced an increase in apoptosis compared to untreated control animals (10.39 ± 8.14%, P ¼ 0.002). In sections from tumors treated with Ad.Egr-TNF þ 20 Gy, tumor endothelial cell apoptosis at 4 and 24 h post-treatment was significantly higher than both 20 Gy alone (Po0.01) and Ad.Egr-TNF alone (Po0.001). Importantly, there was no increase in TAEC apoptosis in TNFR1,2À/À animals treated with Ad.Egr-TNF alone compared with untreated control (P ¼ 0.26) or Ad.Egr-TNF þ 20 Gy compared with 20 Gy alone (P ¼ 0.42). These results indicate that the TAEC is the principal target for Ad.Egr-TNF radiosensitization.
Discussion
Here, we report using a radioinducible adenoviral vector, which expresses TNF-a that increasing TNF-a concentrations above the physiological range exerts radiosensitizing antitumor effects principally by the induction of TAEC apoptosis. These results, in part, explain the activity of TNFerade in different tumor types in humans, as tumor cell resistance to TNF-a or radiation therapy (for example, melanoma, sarcoma) did not preclude dramatic clinical responses. These results support targeting the tumor stroma, which is less likely to show resistance to DNA-damaging agents than more genetically unstable tumor cells. Also, mitotic tumor endothelia may be more sensitive to TNF þ IR than quiescent normal endothelia. In contrast to increasing intratumoral TNF-a concentrations, disruption or blockade of endogenous TNF-TNFR signaling in tumors and/or tumor stroma also results in tumor radiosensitivity. Furthermore, TNF-a secreted by macrophages and other inflammatory cells are important in activating tumor angiogenesis. [36] [37] [38] Interestingly, mice with germline mutations in TNFR1 do not form lung metastasis after tail vein injection of tumor cells as effectively as normal mice, because of a defect in tumor angiogenesis as a result of altered TNF signaling. 39 Together these reports suggest an essential role for TNF-a in tumor angiogenesis. These results are consistent with our histological comparison of the tumor vasculature in C57BL/6 and TNFR1,2À/À mice, in which there is a higher background apoptotic rate and less endothelial cells/per high power field in the untreated TNFR1,2À/À animals. Our findings are the first to show that increasing intratumoral TNF-a concentrations or blocking TNF-TNFR signaling pathways enhance antitumor effects of radiotherapy. Recently, blocking TNF-a was reported to protect against lung damage 40 from radiation in contrast to reports of TNF-a radioprotecting the bone marrow. 41 These seemingly disparate tumor and normal tissue effects of TNFa are likely related to whether TNF-a engages the nuclear factor-kB survival pathway or apoptotic signaling through activation of caspases in tumor-associated or normal endothelial cells. 42 Our results, therefore, provide support for two translational strategies to improve outcomes in clinical radiation therapy. The first strategy is to increase TNF-a concentrations in the tumor through the use of a radiationinducible adenoviral vector (TNFerade). Administration of TNFerade has been shown to be feasible clinically through direct tumor injection or by endoscopic or radiographic delivery in clinical settings where perfusion is impractical. The use of TNFerade is applicable to many tumors currently treated with potentially curative radiotherapy including treatment of patients with limited (oligo)metastatic tumors. 43 The second translational strategy is the use of neutralizing antibodies, 44 small molecules 45 or soluble receptors to block TNF-a effects on tumor and stroma. 46 This strategy has been shown to be feasible and effective in large clinical trials in a variety of collagen vascular diseases including rheumatoid and psoriatic arthritis. 47, 48 In summary, we propose modulation of TNF-a concentrations as a translational approach for improving radiation therapy. funded by Grant CA111423 from the NCI, Ludwig Center for Metastasis Research, the Center for Radiation Therapy, and a gift from Mr and Mrs Vincent Foglia. Dr Weichselbaum and Dr Kufe have an interest in GenVec and are consultants to GenVec. Dr King is employed by GenVec.
